Current progress in dengue vaccines

Shu Wen Wan, Chiou Feng Lin, Shuying Wang, Yu Hung Chen, Trai Ming Yeh, Hsiao Sheng Liu, Robert Anderson, Yee Shin Lin

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Abstract

Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

Original languageEnglish
Article number37
JournalJournal of Biomedical Science
Volume20
Issue number1
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • Dengue
  • Immunopathogenesis
  • Vaccine

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Pharmacology (medical)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Current progress in dengue vaccines'. Together they form a unique fingerprint.

Cite this